Inran 150 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Ranitidine hydrochloride |
| Company | Monicopharma ltd |
Indications
- Treatment of active duodenal ulcer
- Benign gastric ulcer
- Treatment & prevention of ulcer associated with non-steroidal anti-inflammatory agent
- Post operative stress ulcer
- Zollinger-Ellison Syndrome
- Gastroesophageal reflux disease (GERD)
- Gastro-intestinal haemorrhage from stress ulcer in seriously ill patient
- Recurrent haemorrhage in patients with bleeding peptic ulcer
- Before general anesthesia in patient considered to be at risk of acid aspiration particularly obstetric patients
Pharmacology
Ranitidine competitively blocks histamine at H2-receptors of the gastric parietal cells which inhibits gastric acid secretion. It does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion or serum gastrin.
Dosage & Administration
- Ranitidine Tablet & Syrup:
- Usual dosage: 150 mg twice daily for 4 to 8 weeks
- Reflux oesophagitis: 150 mg twice daily or 300 mg at bed time for up to 8 weeks
- Zollinger Ellison syndrome: 150 mg 3 times daily, increased if necessary up to 6 g daily in divided doses
- Episodic dyspepsia: 150 mg twice daily or 300 mg at bed time for up to 6 weeks
- Maintenance: 150 mg at night for preventing recurrences
- Child (peptic ulcer): 2-4 mg/kg twice daily, maximum 300 mg daily
- Ranitidine IV injection & IV Infusion: Dosage based on condition and patient category
Interaction
May interact with propantheline bromide, coumarin anticoagulants, theophylline, diazepam, propanolol, pH-dependent drugs, and antacids
Contraindications
Patients hypersensitive to Ranitidine
Side Effects
- Altered bowel habit
- Dizziness
- Rash
- Tiredness
- Reversible confusional states
- Headache
- Decreased blood counts
- Muscle or joint pain
Pregnancy & Lactation
- Pregnancy: Ranitidine crosses the placenta. Consider usage only if essential
- Lactation: Caution should be exercised when the drug is administered to a nursing mother
Precautions & Warnings
Inran should be given in reduced dosage to patients with impaired renal and hepatic function
Use in Special Populations
Use in the elderly patients is similar to that in younger patients
Overdose Effects
No particular problems expected following overdosage. Symptomatic and supportive therapy should be given as appropriate
Therapeutic Class
H2 receptor antagonist
Reconstitution
- Slow IV inj: Inran 50 mg diluted to a concentration ≤2.5 mg/mL with specific solutions
- Intermittent slow IV infusion: Inran 50 mg diluted to a concentration ≤0.5 mg/mL with specific solutions
- Continuous IV infusion: Inran 150 mg diluted in 250 mL with specific solutions
Storage Conditions
Store in a cool and dry place, protect from light